DAFTAR PUSTAKA

1. Bushby, K. *et al*. Diagnosis and management of Duchenne muscular dystrophy , part 1 : diagnosis , and pharmacological and psychosocial management. Lancet Neurol. 9, 77–93 (2010).

2. Birnkrant, D. J. *et al*. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 17, 211–212 (2018).

3. Baiocco, R., Gattinara, P. C., Cioccetti, G. & Ioverno, S. Parents ' Reactions to the Diagnosis of Duchenne Muscular Dystrophy : Associations Between Resolution , Family Functioning , and Child Behavior Problems. 00, 1–9 (2017).

4. Chen, J. M ediators a ffecting f amily f unction in f amilies of c hildren with duchenne. Kaohsiung J. Med. Sci. 24, 514–522 (2008).

5. Landfeldt, E., Lindgren, P., Bell, C. F., Guglieri, M. & Bushby, K. Quantifying the burden of caregiving in Duchenne muscular dystrophy. 906–915 (2016). doi:10.1007/s00415-016-8080-9

6. Spies, S. *et al*. Duchenne muscular dystrophy. Bmj 341, c4364–c4364 (2010).

7. Strober, J. B. Therapeutics in duchenne muscular dystrophy. NeuroRx 3, 225–234 (2006).

8. Emery A. Duchenne muscular dystrophy. (Oxford: Oxford university press, 1993).

9. Matthews, E., *et al* . Corticosteroids for the treatment of Duchenne muscular dystrophy (Review). Cochrane Database Syst. Rev. 3–37 (2016). doi:10.1002/14651858.CD003725.pub4.www.cochranelibrary.com

10. Sussman M. Duchenne muscular dystrophy. J Am Acad Orthop Surg. 10, 138–51 (2002).

11. Strehle, E. & Straub, V. Recent advances in the management of Duchenne muscular dystrophy. 1173–1177 (2015). doi:10.1136/archdischild-2014-307962

12. Birnkrant, D. J. *et al*. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 17, 445–455 (2018).

13. Brooke M, *et al*. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. 39, 475–81 (1989).

14. Eagle, M. et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nuctural ventilation. Neuromuscul. Disord. 12, 926–929 (2002).

15. Essen, A. J. van *et al*. The natural history of Duchenne muscular dystrophy. Analysis of data from Dutch survey and review of age related events. (1997).

16. Muntoni, F., *et al*. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731–740 (2003).

17. Birnkrant, D. J. *et al*. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 17, 347–361 (2018).

18. Birnkrant, D. J. *et al*. The respiratory management of patients with Duchenne muscular dystrophy: A DMD care considerations working group specialty article. Pediatr. Pulmonol. 45, 739–748 (2010).

19. Sultan, A. & Fayaz, M. Prevalence of cardiomyopathy in duchenne and becker ' s musculr dystrophy. 20, 7–13 (2008).

20. Chenard, A. *et al*. Ventricular arrhythmia in Duchenne muscular dystrophy: Prevalence, significance and prognosis. Neuromuscul. Disord. 3, 201–206 (1993).

21. Gulati, S. *et al*. Duchenne Muscular Dystrophy : Prevalence and Patterns of Cardiac Involvement. 389–393

22. Cruz Guzmán, O. *et al*. Muscular dystrophies at different ages: Metabolic and endocrine alterations. Int. J. Endocrinol. 2012, (2012).

23. Leung, D. *et al*. Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA. Neuromuscul. Disord. 21, 594–601 (2011).

24. Bushby, K. *et al*. Diagnosis and management of Duchenne muscular dystrophy , part 2 : implementation of multidisciplinary care. Lancet Neurol. 9, 177–189 (2010).

25. Marsh, G. G. & Munsat, T. L. Evidence for early impairment of verbal intelligence in Duchenne muscular dystrophy. 118–122 (1974).

26. Alman BA, Raza SN, B. W. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Jt. Surg Am 86, 519–24 (2004).

27. Bianchi, M. L. Osteoporosis in children and adolescents. Bone 41, 486–495 (2007).

28. Goodman, R. Psychometric properties of the strengths and difficulties questionnaire. J. Am. Acad. Child Adolesc. Psychiatry 40, 1337–1345 (2001).

29. Varni, J. W. & Limbers, C. A. The Pediatric Quality of Life Inventory: Measuring Pediatric Health-Related Quality of Life from the Perspective of Children and Their Parents. Pediatr. Clin. North Am. 56, 843–863 (2009).

30. Suthar R, Sankhyan N. Duchenne Muscular Dystrophy : A Practice Update. Indian J Pediatr. (2017).

31. Wein N, Alfano L, Flanigan KM. Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. *Pediatr Clin North Am*. 2015;62:723–42.

32. Al-Dahhak R, Kissel JT. Medical Management of Duchenne Muscular Dystrophy: In: Chamberlain JS, Rando TA, editors. Duchenne Muscular Dystrophy: Advances in Therapeutics. New York London: Taylor and Francis Inc. p. 123–35 (2006)

33. Sussman MM. Duchenne Muscular Dystrophy. *J Am Acadamey Orthop Surg* [Internet].2002;10:138–51.Availablefrom: http://journals.lww.com/jaaos/Abstract/2002/03000/Duchenne_Muscular_Dystrophy.9.aspx (2002).

34. Apkon SD, *et al*. Orthopedic and surgical management of the patient with Duchenne musculardystrophy. *Pediatrics* ;142:S82–9 (2018).

35. Archer JE, *et.al*. Duchennemuscular dystrophy: the management of scoliosis. *J Spine Surg*. 2:185–94 (2016).

36. Liang W, *et.al*. ScienceDirect The natural history of the patients with Duchenne muscular dystrophy in Taiwan : A medical center experience. *Pediatr Neonatol* [Internet]. 2017;1–8. Available from: http://dx.doi.org/10.1016/j.pedneo.02.004 (2017).

37. Emery A. Duchenne Muscular Dystrophy [Internet]. second edi. Motulsky AG, Harper PS, Borrow M, Scriver C, editors. New York; 38 p. Available from: Oxford University Express (1993).

38. Case LE, *et al*. Rehabilitation management of the patient with Duchenne musculardystrophy. *Pediatrics* ;142:S17–33 (2018).

39. Iskandar K, *et al*. The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: The era of personalized medicine. *BMC ResNotes*[Internet].12:1–6. Available from: https://doi.org/10.1186/s13104-019-4730-1 (2019).

40. Varni JW, Planning U. Pediatric Quality of Life Inventory™ PedsQL. (2017).

41. Upton P, Lawford J, Eiser C. Parent-child agreement across child health-related quality of life instruments: A review of the literature. *Qual Life Res*. 17:895–913 (2008),

42. Cavazza M, *et al*. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. *Eur J Heal Econ*.19–29 (2016).

43. Baiardini I, *et.al*. of Child Neurology Quality of Life in Duchenne Muscular Dystrophy : Subjective Impact on Children and Parents. (2011).

44. Deighton A, *et.al*. Pro63 the Natural History of Duchenne Muscular Dystrophy in the Corticosteroid Era:a Systematic Review of Studies From Canada and the Us. *Value Heal* [Internet]. 2019;22:S852. Availablefrom: https://doi.org/10.1016/j.jval.2019.09.2393 (2019).

45. American Thoracic Society. Respiratory Care of the Patient with Duchenne Muscular Dystrophy. *Am J Respir Crit Care Med*.170:456–65 (2004).

46. Le Rumeur E. Dystrophin and the two related genetic diseases, duchenne and becker muscular dystrophies. *Bosn J Basic Med Sci*.15:14–20 (2015)

47. Nascimento Osorio A, *et.al*. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. *Neurol (English Ed* [Internet]. 2019;34:469–81. Available from: http://dx.doi.org/10.1016/j.nrleng.2018.01.001)2018).

48. Toussaint M, *et.al*. Cough augmentation insubjects with duchenne muscular dystrophy: Comparison of air stacking via a resuscitator bag versus mechanical ventilation. *Respir Care*. 61:61– 7 (2016).

49. Buddhe S, *et al.* Cardiac management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 142:S99–106 (2018).

50. Mavrogeni SI, *et.al*. Duchenne Muscular Dystrophy: Methods and Protocols, Methods in Molecular Biology. In: Bernadini C, editor. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. SpringerScience + Business Media . p. 3(2018).

51. Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. *Neuromuscul Disord*.15:86–7 (2005).

52. Farrar M, Perera N. Bone Health in Children with Duchenne Muscular Dystrophy: A Review. *Pediatr Ther*. 05:252 (2015).

53. Bell KL, *et.al*. Use of Segmental Lengthsfor the Assesment of Growth in Children with Cerebral Palsy. *Handb AnthrPhys Meas Hum Form Heal Dis*. 1279 (2012)

54. Griffith R, Edwars R. A new chart for weight control in Duchenne muscular dystrophy. *Arch Dis Child*. 1256–8 (1998).

55. Matthews E, *et.al*. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review) summary of findings for the main comparison. *Cochrane Database Syst Rev*. (2016).

56. Darras BT, *et.al.* Corticosteroid Therapy in DMD. *Dystrophinopathies Gene Rev*. (2018).